Electrode Positions in Cardioverting Atrial Fibrillation
EPIC
Comparison of Anterior-Posterior Versus Anterior-Lateral Electrode Position in Cardioverting Atrial Fibrillation - A Randomized Clinical Trial
1 other identifier
interventional
468
1 country
3
Brief Summary
Atrial fibrillation is the most common heart rhythm disorder, and the incidence is rapidly increasing. Cardioversion using an electrical shock (DC-cardioversion) is an important treatment to reduce symptoms and improve patient's quality-of-life. The treatment is performed by applying gel electrodes to the chest. Cardioversion is not always successful, and it is unknown which electrode-position provides the optimal efficacy. This study aims to compare two electrode positions, which are in clinical use: Anterior-posterior (left front and left back) versus anterior-lateral (right front and left side of the chest).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable atrial-fibrillation
Started Feb 2019
Shorter than P25 for not_applicable atrial-fibrillation
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 21, 2019
CompletedFirst Posted
Study publicly available on registry
January 25, 2019
CompletedStudy Start
First participant enrolled
February 19, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 2, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 2, 2020
CompletedOctober 8, 2020
October 1, 2020
1.6 years
January 21, 2019
October 6, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Efficacy: First shock success
The primary endpoint will be first shock efficacy, i.e. the proportion of patients in sinus rhythm for at least one minute immediately after an initial shock of 100 J.
Immediately after first cardioversion attempt.
Secondary Outcomes (3)
Efficacy: Successful cardioversion
One minute after cardioversion
Safety: Number of participants with arrhythmic events during and after cardioversion
Within 2 hours after cardioversion (until discharge)
Safety: Number of participants with skin-discomfort, skin burns or itching
Two hours after cardioversion (at discharge)
Study Arms (2)
Anterior-posterior electrode position
ACTIVE COMPARATORThe anterior electrode is placed in the left parasternal area (precordium). The posterior electrode is placed in the left lower-scapular region with the electrode edge left to the spinal column.
Anterior-lateral electrode position
ACTIVE COMPARATORThe anterior electrode is placed in the right parasternal area below the clavicle. The lateral electrode is placed with the center of the electrode in the left mid-axillary line in level with the V6 electrocardiogram electrode.
Interventions
Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-posterior electrode position
Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-lateral electrode position
Eligibility Criteria
You may qualify if:
- Atrial fibrillation (documented on an ECG-12)
- Able and willing to sign informed consent
- Age ≥ 18 years
- Anticoagulation according to guidelines (Patients with atrial fibrillation for \>48 hours will be required to have a documented weekly international normalized ratio (INR) ≥2.0 (including within 48 hours of cardioversion) or treatment with non-vitamin K oral anticoagulant for three weeks or longer. Alternatively, a transoesophageal echocardiogram documenting the absence of intracardiac thrombi is accepted and cardioversion can be performed on treatment with low molecular weight heparin).
You may not qualify if:
- Implanted pacemaker and/or cardioverter defibrillator (ICD)
- Prior enrollment in the trial
- Hemodynamically unstable atrial fibrillation
- Untreated hyperthyroidism
- Known or suspected pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Aarhuslead
- Regionshospitalet Viborg, Skivecollaborator
- Randers Regional Hospitalcollaborator
- Regionshospitalet Horsenscollaborator
Study Sites (3)
Horsens Regional Hospital
Horsens, 8700, Denmark
Randers Regional Hospital
Randers, 8930, Denmark
Viborg Regional Hospital
Viborg, 8800, Denmark
Related Publications (1)
Schmidt AS, Lauridsen KG, Moller DS, Christensen PD, Dodt KK, Rickers H, Lofgren B, Albertsen AE. Anterior-Lateral Versus Anterior-Posterior Electrode Position for Cardioverting Atrial Fibrillation. Circulation. 2021 Dec 21;144(25):1995-2003. doi: 10.1161/CIRCULATIONAHA.121.056301. Epub 2021 Nov 24.
PMID: 34814700DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anders S Schmidt, MD
Randers Regional Hospital
- STUDY DIRECTOR
Consultant cardiologist Andi E Albertsen, MD, PhD
Viborg Regional Hospital
- STUDY CHAIR
Professor Bo Løfgren, MD, PhD, FESC, FAHA
University of Aarhus
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 21, 2019
First Posted
January 25, 2019
Study Start
February 19, 2019
Primary Completion
October 2, 2020
Study Completion
October 2, 2020
Last Updated
October 8, 2020
Record last verified: 2020-10